Luis Villela

6PUBLICATIONS
43CO-AUTHORS
Haematological tumoursPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Disease surveillanceCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 11, 2026
Latin American Consensus for the Diagnosis, Staging, and Treatment of Peripheral T-Cell Lymphoma Not Otherwise Specified.

|Oct 27, 2025
Prognostic relevance of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis and dose-response evidence.

Rafael Pichardo-Rodriguez, José M Vela-Ruiz, Luis Villela

|May 22, 2025
Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Systematic Review.

|May 14, 2025
Comparing Hodgkin and Non-Hodgkin Lymphoma Mortality Between Latin America and the United States From 2008 to 2019: The Need of Regional-Based Lymphoma Registries.

Bryan Valcarcel, German Stemmelin, Sofia Rivarola

|Nov 19, 2024
Optimizing resources: low-dose nivolumab combinations in the management of relapsed/refractory Hodgkin lymphoma.

Perla R Colunga-Pedraza, Héctor A Vaquera-Alfaro, Zulia Guzmán-Martínez

|Nov 03, 2022
Non-Hodgkin lymphoma treatment in middle-income countries in Latin America: perspective of the Latin American Study Group of Lymphoproliferative Disorders [Grupo de Estudio de Linfoproliferativos de Latino América (GELL)].

Luis Villela, María Torre-Viera, Henry Idrobo-Quintero

Pageof 1

Frequent Collaborators

3 joint publications

Perla R Colunga-Pedraza

3 joint publications

Maria-Alejandra Torres Viera

3 joint publications

Luis Malpica

3 joint publications

Brady Ernesto Beltran